Brokerages Set Immuneering Corporation (NASDAQ:IMRX) Target Price at $16.50

Immuneering Corporation (NASDAQ:IMRX) has been assigned a consensus recommendation of “Moderate Buy” from the seven ratings firms that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, five have issued a buy rating and one has assigned a strong buy rating to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $16.50.

Several research analysts have issued reports on the stock. Wall Street Zen upgraded shares of Immuneering from a “sell” rating to a “hold” rating in a research report on Sunday, April 19th. Weiss Ratings restated a “sell (d-)” rating on shares of Immuneering in a research report on Friday, March 27th. Finally, Needham & Company LLC restated a “buy” rating and issued a $11.00 price target on shares of Immuneering in a research report on Monday, March 9th.

Hedge Funds Weigh In On Immuneering

Several institutional investors and hedge funds have recently added to or reduced their stakes in IMRX. Sanofi purchased a new position in Immuneering during the 3rd quarter worth approximately $18,960,000. Empery Asset Management LP purchased a new position in Immuneering during the 4th quarter worth approximately $17,601,000. State Street Corp grew its position in Immuneering by 1,289.7% during the 4th quarter. State Street Corp now owns 2,402,238 shares of the company’s stock worth $15,807,000 after purchasing an additional 2,229,374 shares in the last quarter. Vanguard Group Inc. grew its position in Immuneering by 128.5% during the 3rd quarter. Vanguard Group Inc. now owns 2,415,244 shares of the company’s stock worth $16,907,000 after purchasing an additional 1,358,322 shares in the last quarter. Finally, Citadel Advisors LLC purchased a new position in Immuneering during the 3rd quarter worth approximately $6,602,000. 67.65% of the stock is currently owned by hedge funds and other institutional investors.

Immuneering Stock Performance

Immuneering stock opened at $4.87 on Tuesday. The firm has a market cap of $315.07 million, a price-to-earnings ratio of -4.16 and a beta of 0.37. Immuneering has a 1 year low of $1.40 and a 1 year high of $10.08. The firm’s 50 day moving average price is $5.34 and its two-hundred day moving average price is $5.69.

Immuneering (NASDAQ:IMRX) last posted its quarterly earnings results on Friday, May 15th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.09. As a group, equities analysts predict that Immuneering will post -1.39 EPS for the current fiscal year.

About Immuneering

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.